2022
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery 2022, 21: 529-540. PMID: 35701637, DOI: 10.1038/s41573-022-00493-5.Peer-Reviewed Original ResearchConceptsAdaptive immune resistanceImmune resistanceCell death 1 ligand 1Tumor siteDeath 1 ligand 1Anti-PD therapyBlockade of PDL1Advanced-stage cancerFraction of patientsStrong mechanistic rationaleFuture drug developmentCurrent cancer therapiesImmune attackClinical trialsSolid tumorsTherapeutic opportunitiesTumorsCancer therapySelective inductionAntitumour drugsLigand 1Drug developmentTherapyAdditive effectMechanistic rationale
2003
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial. JAMA 2003, 290: 2149-2158. PMID: 14570950, DOI: 10.1001/jama.290.16.2149.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerRadiographic tumor regressionPartial radiographic responseCell lung cancerRadiographic responseTumor regressionEpidermal growth factor receptorOral gefitinibLung cancerOral EGFR tyrosine kinase inhibitorRandomized phase 2 trialEGFR tyrosine kinase inhibitorsAcne-like rashCommunity oncology centersPhase 2 trialLung cancer symptomsPhase 1 trialEfficacy of gefitinibDisease-related symptomsFraction of patientsGrowth factor receptorNSCLC symptomsChemotherapy regimensEpidermal growth factor receptor tyrosine kinaseOverall survival